60 results about "Inhalant Solution" patented technology

An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.

The invention discloses an atomized inhalant for treating respiratory system diseases. The atomized inhalant mainly prepared from, by mass, 1%-2% of 1,8-cineole, 1%-4% of solubilizers and 20%-90% of water. The inhalant is used through the steps that a medicine solution is atomized into small particles, and the small particles are inhaled into the nose, the throat, the respiratory tract and the lung, so that the medicine is deposited on the lesions to treat the diseases. The atomized inhalant for treating the respiratory system diseases treats patients who suffer from acute and chronic faucitis, rhinitis, asthma, obstructive (spastic) bronchitis, chronic bronchitis, bronchiectasia, mucoviscidosis, cysticfibrosis and chronic obstructive pneumonia and need to humidify the tracheae and dilute the sputum. The inhalant has the advantages that the effect is achieved quickly, the medicine using amount is little, use is convenient, and the safety is high.

The invention discloses a formulation of an alpha-interferon dry powder inhalant and a method for producing the same. The method comprises the following steps: adding a protective agent mainly comprising tween-80 into an alpha-interferon first; preparing the mixture into the dry powder inhalant mainly comprising the alpha-interferon through rotary evaporation and vacuum freezing and drying; and filling the dry powder inhalant into a rotary inhaler to prepare a finished product. The method prolongs the storage time of the interferon, and the interferon is convenient to use and advantageous for absorbing, thus the clinical using effect of the alpha-interferon is brought into play better.

The invention discloses a medical product for use in a treatment of respiratory disorders, and comprises a metered dose of a tiotropium dry powder formulation, directly loaded and sealed into a container made to act as a dry high barrier seal to prevent the capture and ingress of moisture into the tiotropium powder. The dose of tiotropium is further adapted for inhalation and the container is so tight that the efficacy of the dose when delivered is unaffected by moisture. In a further aspect of the invention a type of inhaler is illustrated, which may accept at least one sealed, moisture-tight container of a dose of tiotropium, to deliver the dose with a consistent fine particle dose, over the expected shelf life of the product.

The invention relates to the technical field of oxygen delivery masks, and discloses an oxygen delivery mask suitable for lung disease treatment, which comprises a mask body, wherein a pipeline is mounted on one side of the mask body, a communicating pipe is mounted at the bottom end of the pipeline in a threaded manner, a three-way connector is mounted at the bottom end of the communicating pipe, and an oxygen delivery pipe is mounted on one side of the three-way connector. A three-way connector is arranged in the pipeline, a medicament pipe is arranged at the bottom end of the three-way connector, a plug is arranged in the bottom of the pipeline, a spiral groove is formed in the side wall of the plug, and a spiral channel is formed between the plug and the pipeline. According to the oxygen therapy mask, oxygen supply can be achieved while medicine gas supply is guaranteed, so that firstly, oxygen supply and medicine taking can be conducted at the same time, and secondly, due to the fact that oxygen supply can be conducted during medicine supply, the risk caused by oxygen interruption when a critical patient inhales medicine is reduced, and further due to continuous oxygen supply, the patient can be ensured to be in a relatively stable state, so that a good inhalant treatment effect is also ensured.

The invention provides a compound dry powder inhalant which comprises baicalin, ambroxol hydrochloride, L-leucine and phosphate, the mass of the compound dry powder inhalant is as follows: the L-leucine accounts for 0-50%, the mass of the phosphate accounts for 15-35%, the total mass of the baicalin and the ambroxol hydrochloride accounts for 15-85%, and the mass ratio of the baicalin to the ambroxol hydrochloride is 1:(0.2-2); and the Dv90 of the compound dry powder inhaler is less than or equal to 5 microns. The combination of baicalin and ambroxol hydrochloride can effectively reduce inflammation and oxidative damage of lung tissues, relieve pulmonary edema and histopathologic change, and relieve pulmonary dysfunction and fibrosis. The compound dry powder inhalant is administrated through the lung, so that the half-life period and the in-vivo residence time of the medicine in plasma are obviously prolonged, the bioavailability of the medicine in lung tissue is improved, the clearance rate of the medicine in the lung tissue is reduced, the residence time of the medicine in the lung is prolonged, and the medicine can fully play a role in the lung tissue.

The invention relates to the field of inhalant devices, in particular to an inhalant device favorable for inhalant to enter deep part of lung. The device comprises a shell, the shell is provided witha storage part used for containing a medicine storage tank and an inhalation part used for inhaling medicine by a patient. The inhalant device further comprises a threshold switch, the threshold switch has a braking state and an opening state, the threshold value of the threshold switch is matched with the value of negative pressure generated in the inhalation part when the patient inhales from the inhalation part, and when the threshold switch is in the braking state, the medicine is stopped, so that the patient cannot inhale the medicine through the inhalation part; and when the value of thenegative pressure generated when the patient inhales from the inhalation part is equal to or larger than the threshold value, the threshold value switch is changed from the braking state to the opening state and kept in the opening state, and the patient can inhale the medicine from the inhalation part. In the scheme of the invention, the medicine can enter the lung at a relatively high flow rate, so that a good medicine supply effect and a good treatment effect can be achieved, and the adverse reaction risk of medicament use is greatly reduced.

The invention relates to the field of inhalant devices, and specifically relates to an inhalant device. The inhalant device comprises a shell, wherein a storage part for placing a drug storing pot andan inhalation part for a patient to inhale a medicament are arranged on the shell, and a medicament cavity communicating with the inhalation part is further formed in the shell and cooperates with the drug storing pot, and the medicament enters the medicament cavity when being sprayed from the drug storing pot; and a detection device for detecting the dose of the medicament in the medicament cavity is arranged on the inhalation part. The inhalant device provided by the invention can be used for monitoring the actual dose of the medicament inhaled by a patient, and when a detection result displays that the medicament is remained in the medicament cavity, the residual medicament can be inhaled by the patient again until being completely inhaled, so that the sufficient dose of the medicamentis guaranteed, and a good treatment effect is guaranteed.

The invention discloses an aerosol inhalant and a preparation method thereof. The aerosol inhalant comprises the following components: active components including umeclidinium bromide and vilanterol triphenyl acetate, a solubilizer, a bacteriostatic agent and a solution carrier. In addition, the invention also discloses a pharmaceutical composition. The active components, namely the umeclidinium bromide and the vilanterol triphenyl acetate, of the aerosol inhalant are good in stability, propellants are not contained, and the prepared aerosol inhalant is small in particle size and beneficial for pulmonary absorption of medicines. The preparation method for the aerosol inhalant is simple in production process, good in repeatability and suitable for industrial production.

The invention relates to an inhalant used for inhibiting coronavirus, and a preparation method and application of the inhalant, and belongs to the technical field of pharmaceutical preparations. The inhalant comprises Remdesivir and / or a pharmaceutically acceptable salt thereof. According to the inhalant used for inhibiting the coronavirus, due to adoption of small-dose pulmonary administration,effective pulmonary administration concentration can be achieved when micronized or aerosolized Remdesivir is inhaled, the coronavirus, especially the novel coronavirus, can be effectively inhibited, the defects of a narrow treatment window and poor safety in the prior art are overcome, a small dosage is given for multiple times, so that the inhalant can be accumulated in the lung so as to form an effective virus inhibition effect, a curative effect can be improved or the dosage of the Remdesivir is reduced, and potential side effects are reduced.

The present invention relates to a sensor module (110) and a method (210) for determining an administration rate of an aerosol of an aerosol stream (112), where the aerosol stream (112) is provided to a patient through an inhalation device, and to an inhalation device. Here, the sensor module (110) comprises:-an adaptive structure (160) designed to attach the sensor module (110) to the suction device; -measuring a volume (114); -a concentration measurement unit (124) designed to generate at least one first measurement signal as a function of an aerosol concentration in the measurement volume (114); a flow measuring unit which is designed to generate at least one second measurement signal as a function of the flow of the aerosol flow (112) through the measurement volume (114), the flow measuring unit comprising a pressure measuring unit (140), the pressure measuring unit (140) comprising a differential pressure sensor (148), the differential pressure sensor (148) being designed to measure the flow of the aerosol flow (112) through the measurement volume (114). Wherein a first port (146) of the differential pressure sensor (148) is designed to determine a first pressure in front of a flow collection structure (152) contained in the measurement volume (114), and wherein a second port (154) of the differential pressure sensor (148) is designed to determine a second pressure behind the flow collection structure (152), wherein the differential pressure sensor (148) is adapted to generate at least one second measurement signal as a function of a difference between the first pressure and the second pressure; and-an evaluation unit (156) designed to determine the administration rate of the aerosol in the inhalation device on the basis of a simultaneous determination of the aerosol concentration from the at least one first measurement signal and the inhalation flow from the at least one second measurement signal. The sensor module (110) and method (210) allow for accurate determination of the administration rate of aerosol actually received by a patient from an aerosol stream (112) when using the inhalation device, the inhalation dose per respiration, and the total inhalation dose per application. The sensor module (110) may be used with existing or novel inhalation devices that benefit from the determination of the actually received aerosol administration rate, while the patient may continue to use a familiar inhalation device.